Used in antibody-drug conjugates (ADCs) to enable targeted delivery of cytotoxic agents to cancer cells. The linker is designed to remain stable in circulation but release the drug inside the tumor cell upon internalization and lysosomal degradation. Its glucuronide component allows for enzymatic cleavage by β-glucuronidase, an enzyme overexpressed in the tumor microenvironment, enhancing site-specific drug release. This improves therapeutic efficacy while reducing systemic toxicity. Commonly employed in oncology drug development, particularly in solid tumor treatments.